• Skip to main content
  • Skip to footer

Akari Therapeutics

AN INNOVATIVE TARGETED ONCOLOGY COMPANY BUILT ON NEXT GENERATION ANTIBODY-DRUG CONJUGATES (ADC) AND A NOVEL DISCOVERY ENGINE

Menu
  • HOME
  • ABOUT
    • Close
    • COMPANY OVERVIEW
    • MANAGEMENT
    • BOARD OF DIRECTORS
    • CEO CORNER
    • SCIENTIFIC ADVISORY BOARD
  • AREAS OF FOCUS
    • Close
    • PIPELINE
    • POSTERS & PUBLICATIONS
  • INVESTOR RELATIONS
    • Close
    • OVERVIEW
    • CORPORATE GOVERNANCE
      • Close
      • GOVERNANCE OVERVIEW
      • BOARD OF DIRECTORS
      • MANAGEMENT
      • COMMITTEE COMPOSITION
    • FINANCIAL INFORMATION
      • Close
      • SEC FILINGS
      • ANNUAL REPORTS
    • NEWS & PRESENTATIONS
      • Close
      • PRESS RELEASES
      • PRESENTATIONS
    • ANALYST COVERAGE
    • STOCK INFORMATION
      • Close
      • STOCK QUOTE & CHART
      • HISTORIC PRICE LOOKUP
    • EMAIL ALERTS
  • PRESS
    • Close
    • PRESS RELEASES
  • CONTACT US

Akari TX / October 1, 2026

General Meeting of Shareholders (GM) to be held on October 28, 2026

NOTICE OF GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON OCTOBER 28, 2026 (CLICK TO VIEW AND DOWNLOAD)

PROXY FORM (CLICK TO VIEW AND DOWNLOAD)

Loading Viewer...

Filed Under: Notices

Footer

FOLLOW US

X
LINKEDIN
Youtube
Terms of Use
Privacy Statement
Contact Us

Akari TX

Copyright © 2026 · Akari Therapeutics · Site Designed by Polus Digital, Inc.